Similar articles for PMID: 21707956

Year	Number of Results
2006	1
2007	4
2008	6
2009	15
2010	6
2011	12
2012	16
2013	12
2014	12
2015	5
2016	9
2017	2
2018	1
2019	4
2020	4
2021	7
2022	5
2023	2
2024	0

1

Stonehouse AH, Darsow T, Maggs DG. Stonehouse AH, et al. J Diabetes. 2012 Mar;4(1):55-67. doi: 10.1111/j.1753-0407.2011.00143.x. J Diabetes. 2012. PMID: 21707956 Free PMC article. Review.

2

Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction.

Russell S. Russell S. Int J Clin Pharm. 2013 Apr;35(2):159-72. doi: 10.1007/s11096-012-9729-9. Epub 2012 Dec 22. Int J Clin Pharm. 2013. PMID: 23263796 Review.

3

Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes.

Cornell S. Cornell S. J Clin Pharm Ther. 2012 Oct;37(5):510-24. doi: 10.1111/j.1365-2710.2012.01342.x. Epub 2012 Mar 21. J Clin Pharm Ther. 2012. PMID: 22436069 Review.

4

Beyond glycemic control: cardiovascular effects of incretin-based therapies.

Angeli FS, Shannon RP. Angeli FS, et al. Front Horm Res. 2014;43:144-57. doi: 10.1159/000360598. Epub 2014 Jun 10. Front Horm Res. 2014. PMID: 24943305 Review.

5

Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.

Jellinger PS. Jellinger PS. Postgrad Med. 2011 Jan;123(1):53-65. doi: 10.3810/pgm.2011.01.2245. Postgrad Med. 2011. PMID: 21293084 Review.

6

Incretin-based therapies for type 2 diabetes mellitus.

Lovshin JA, Drucker DJ. Lovshin JA, et al. Nat Rev Endocrinol. 2009 May;5(5):262-9. doi: 10.1038/nrendo.2009.48. Nat Rev Endocrinol. 2009. PMID: 19444259 Review.

7

Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors.

Nauck M. Nauck M. Diabetes Obes Metab. 2016 Mar;18(3):203-16. doi: 10.1111/dom.12591. Epub 2016 Jan 5. Diabetes Obes Metab. 2016. PMID: 26489970 Free PMC article. Review.

8

Combination pharmacotherapy with incretins: what works best and when?

Over RK, Ratner RE. Over RK, et al. Curr Diab Rep. 2008 Oct;8(5):361-7. doi: 10.1007/s11892-008-0063-5. Curr Diab Rep. 2008. PMID: 18778584

9

Recent advances in incretin-based therapies.

Russell-Jones D, Gough S. Russell-Jones D, et al. Clin Endocrinol (Oxf). 2012 Oct;77(4):489-99. doi: 10.1111/j.1365-2265.2012.04483.x. Clin Endocrinol (Oxf). 2012. PMID: 22804841 Review.

10

Incretin-based treatment of type 2 diabetes: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors.

Deacon CF. Deacon CF. Diabetes Obes Metab. 2007 Sep;9 Suppl 1:23-31. doi: 10.1111/j.1463-1326.2007.00765.x. Diabetes Obes Metab. 2007. PMID: 17877544 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

113 results

Results by year